Tarsus Pharmaceuticals, Inc. (TARS) stock
TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/309% above fair value
$80.28+3.39 (+4.41%)
Close on Nov 13, 2026Market cap $3.52BP/E –Yield 0.00%
Tarsus Pharmaceuticals enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Tarsus Pharmaceuticals's enterprise value was $2.94B on Nov 11, 2026, against $3.06B a year earlier. Over the last 5 years it ranged from $128.76M to $3.15B, with a median of $975.63M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $2.94B | -6.4% |
| 2025 | Dec 31, 2025 | $3.15B | +68.3% |
| 2024 | Dec 31, 2024 | $1.87B | +312.6% |
| 2023 | Dec 29, 2023 | $453.18M | +146.6% |
| 2022 | Dec 30, 2022 | $183.79M | -34.7% |
| 2021 | Dec 31, 2021 | $281.30M | +751.6% |
| 2020 | Dec 31, 2020 | $33.03M | – |
See a number that looks wrong?